Egypt's 2025 Tax Overhaul and What It Means for Healthcare Providers, Pharmacies and Medical Suppliers

Egypt moved through an unusually active legislative year for taxation in 2025, and healthcare operators sit squarely within the changes despite the long-standing rule that medical services themselves remain exempt from value added tax. Providers that assume the exemption shelters them from the wider reform agenda are mistaken. The combined effect of the amended VAT Law, the accelerating electronic documentation regime and the small-enterprise incentive package touches almost every hospital, clinic, pharmacy, laboratory and pharmaceutical distributor in the country.

The headline change came with Law No. 157 of 2025, which amended VAT Law No. 67 of 2016 and took effect on 18 July 2025. The law did not alter the core exemption for medical care, prescription medicines or healthcare services delivered by licensed professionals, and that continuity is welcome for the sector. What it did change matters for ancillary activity. The exemption previously enjoyed by advertising services was narrowed sharply, so that only advertisements soliciting donations for treatment and medical care retain relief. Healthcare groups that run paid promotional campaigns, market elective or cosmetic services, or advertise on behalf of for-profit facilities now face the general fourteen percent rate on those supplies. Separately, contracting and construction services moved from a five percent scheduled rate to the general fourteen percent rate. Any hospital, diagnostic centre or pharmaceutical plant undertaking a build-out, fit-out or expansion should reprice capital projects accordingly, while noting that the shift to the standard rate now permits input VAT recovery that was previously unavailable under the scheduled regime.

The more pervasive shift is procedural rather than rate-based. The Egyptian Tax Authority continued its phased rollout of mandatory electronic invoicing and electronic receipts through 2025. Under ETA Decision No. 281 of 2025, an additional cohort of taxpayers became obliged to issue electronic receipts for business-to-consumer transactions from 15 September 2025, part of the eighth sub-phase of the e-receipt deployment. For healthcare, this is the operationally significant development. A pharmacy selling over the counter to walk-in patients, a clinic charging consultation fees, a laboratory billing individuals, or a private hospital invoicing self-paying patients all generate B2C transactions that increasingly must be captured through point-of-sale or ERP systems integrated with the Authority's central platform. The Authority has been explicit that transactions not documented through the approved digital channels will not be recognised for the purpose of cost verification, expense deduction or VAT refund claims. A provider that fails to integrate therefore risks losing the ability to substantiate its own costs, even where the underlying supply is exempt or zero-rated.

For smaller players, Law No. 6 of 2025, published in February and effective from 1 March 2025, offers a counterweight of relief. The law introduces a simplified regime for enterprises with annual turnover not exceeding twenty million Egyptian pounds, a threshold that captures a large share of single-site clinics, independent pharmacies, physiotherapy centres and small diagnostic labs. Qualifying entities benefit from sharply reduced rates that scale with turnover, quarterly rather than monthly VAT returns, lighter bookkeeping through approved electronic accounting, exemption from stamp tax and documentation charges, and relief on certain capital gains and dividends connected to the activity. Eligible healthcare entrepreneurs should weigh enrolment carefully, because the simplified track trades some flexibility for a materially lower administrative and tax burden. A second facilitation package followed in December, extending compliance-linked benefits such as a White List with one-week VAT refunds and priority service access to taxpayers with clean records. That same package also cut VAT on medical devices from fourteen to five percent and exempted dialysis machine components, a direct saving for facilities investing in equipment.

The interaction with the universal health insurance rollout adds a further compliance layer. Hospitals, clinics, treatment centres and pharmacies contracting into the national insurance system face registration charges ranging from one thousand to fifteen thousand Egyptian pounds, with per-bed fees applying to hospitals. These are regulatory contributions rather than taxes, but they sit alongside the corporate income tax exposure of the sector. Egypt continues to apply a standard corporate income tax rate of 22.5 percent on net taxable profit for most companies, and healthcare operators structured as taxable entities are assessed on that basis irrespective of the VAT exemption on their clinical revenue. The exemption removes VAT from patient billing. It does not remove the entity from the income tax net.

The United Arab Emirates offers a useful comparison for groups operating across both markets. There, healthcare follows a mixed VAT treatment under the five percent standard rate, with preventive and curative services by licensed professionals generally zero-rated, while cosmetic and elective procedures attract the standard rate. Corporate tax of nine percent applies above a taxable income threshold of 375,000 dirhams, with the potential for a zero percent rate for qualifying free zone healthcare entities that avoid mainland-sourced revenue. The structural lesson for cross-border providers is consistent. The clinical exemption or zero-rating is never the end of the analysis. Ancillary services, capital projects, intra-group charges and documentation obligations drive the real compliance workload. Egyptian healthcare operators should treat 2025 as the year to formalise their e-invoicing architecture, reassess the VAT status of every non-clinical revenue stream, and confirm whether the small-enterprise regime delivers a net advantage before the next phase of mandates arrives.